推荐产品
化驗
≥98% (HPLC)
形狀
powder
顏色
white to beige
溶解度
DMSO: 2 mg/mL, clear
儲存溫度
2-8°C
SMILES 字串
C#CC1=CC=CC(NC2=NC3=CC=CC=C3N=C2NC4=CC=CC(C#C)=C4)=C1
InChI 密鑰
SCUPZFSEJFWQIS-UHFFFAOYSA-N
生化／生理作用
TD52, an erlotinib analog, is a putative inhibitor of CIP2A that exhibits potent antitumor efficacy on HCC and TNBC cells. TD52 induces apoptosis through downregulation of CIP2A (Cancerous inhibitor of protein phosphatase 2A) in HCC, NSCLC and TNBC cells. Apparently TD52 indirectly downregulates CIP2A transcripts through interrupting the binding of Elk1 to CIP2A promoter. TD52 is a weak inhibitor of EGFR tyrosine kinase.
putative inhibitor of CIP2A that exhibits potent antitumor efficacy on HCC and TNBC cells.
儲存類別代碼
11 - Combustible Solids
水污染物質分類（WGK）
WGK 3
Chun-Yu Liu et al.
European journal of cancer (Oxford, England : 1990), 72, 112-123 (2016-12-28)
Cancerous inhibitor of protein phosphatase 2A (CIP2A) has emerged as a therapeutic determinant mediating the anti-cancer effects of several new agents. We investigated the efficacy and mechanism of TD52, an erlotinib derivative with minimal p-EGFR inhibition but significant CIP2A downregulation
H-C Yu et al.
Cell death & disease, 5, e1359-e1359 (2014-08-01)
Protein phosphatase 2A (PP2A) is a tumor suppressor, which is functionally defective in various cancers. Previously, we found that PP2A activity determined the anticancer effect of bortezomib and erlotinib in hepatocellular carcinoma (HCC) cells. Here, we tested a novel erlotinib
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系技术服务部门